Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 674.63 |
Low | 674.63 |
Bid | -- |
Offer | -- |
Previous close | 912.70 |
Average volume | 0.00 |
---|---|
Shares outstanding | 75.76m |
Free float | 74.90m |
P/E (TTM) | -- |
Market cap | 3.41bn USD |
EPS (TTM) | -2.74 USD |
Data delayed at least 20 minutes, as of Nov 08 2024.
More ▼
Announcements
- Xenon to Report Q3 2024 Financial Results on November 12, 2024
- Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
- Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
- Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
- Xenon Reports Q2 2024 Financial Results and Business Update
- Xenon to Report Q2 2024 Financial Results on August 8, 2024
- Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
- Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
More ▼